September 20, 2023 03:45 PM EDTUpdated September 21, 05:40 AM

Novo Nordisk’s US semaglutide manufacturing site under the spotlight again as 2022 monitoring issue surfaces

Anna Brown

News Reporter

Reynald Castañeda

Deputy Editor

Novo Nordisk’s US facility has had at least four quality control issues related to microbes in the past two years. Its Clayton, NC site manufactures …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk’s US semaglutide manufacturing site under the spotlight again as 2022 monitoring issue surfaces

Anna Brown

News Reporter

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­vo Nordisk’s US semaglu­tide man­u­fac­tur­ing site un­der the spot­light again as 2022 mon­i­tor­ing is­sue sur­faces

News Reporter

Deputy Editor

Sign up to read this article for free.

Novo Nordisk’s US semaglutide manufacturing site under the spotlight again as 2022 monitoring issue surfaces